Rituximab and Abatacept Are Effective in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies

Rituximab and Abatacept Are Effective in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies

BackgroundInterstitial lymphocytic lung disease (ILLD), a recently recognized complication of primary immunodeficiencies (PID), is caused by immune dysregulation, abnormal bronchus-associated lymphoid tissue (BALT) hyperplasia, with subsequent progressive loss of pulmonary function. Various modes of...

Full description

Bibliographic Details
Main Authors: Yulia Rodina, E. Deripapa, O. Shvets, A. Mukhina, A. Roppelt, D. Yuhacheva, A. Laberko, V. Burlakov, D. Abramov, G. Tereshchenko, G. Novichkova, Anna Shcherbina
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Immunology
Subjects:
ILLD
primary immunodeficiency
children
treatment
rituximab
abatacept
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.704261/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.704261/full

Similar Items